Court Upholds Ortho-McNeil's Topamax Patent

Law360, New York (March 31, 2008, 12:00 AM EDT) -- Mylan Laboratories Inc. suffered another setback in its battle to sell a generic version of the epilepsy drug Topamax, after a federal appeals court on Monday upheld a summary judgment ruling that Ortho-McNeil Pharmaceutical Inc.'s patents for the blockbuster pharmaceutical were valid.

The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey district court's opinion that the Topamax patent was valid until Sept. 26, 2008 and that Mylan should be permanently enjoined from selling generic versions of the drug.

The ruling also enjoined...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.